Brief: Epigenomics Announces Conversion Result Of First Conversion Period Of Mandatory Convertible Bond 2021/2024
20/04/2021 14:42
April 20 (Reuters) - EPIGENOMICS AG ECXn.DE :
* ANNOUNCES CONVERSION RESULT OF THE FIRST CONVERSION PERIOD
OF
THE MANDATORY CONVERTIBLE BOND 2021/2024
* ANNOUNCES THAT CONVERTIBLE BONDS WITH A NOMINAL VALUE OF
EUR
4,357,606.00 HAVE BEEN CONVERTED INTO 3,961,460 NEW SHARES
* IN FIRST CONVERSION PERIOD OF MANDATORY CONVERTIBLE BOND
2021/2024
* NUMBER OF ISSUED SHARES INCREASED FROM 5,891,230 TO
9,852,690 NO
PAR VALUE REGISTERED SHARES OF COMPANY
* COMPANY'S SHARE CAPITAL INCREASES CORRESPONDINGLY BY EUR
3,961,460.00 TO EUR 9,852,690.00
* OUTSTANDING PORTION OF MANDATORY CONVERTIBLE BOND
2021/2024
THEREFORE HAS A NOMINAL VALUE OF EUR 1,142,394.00
* NEW SHARES, WHICH CARRY FULL DIVIDEND RIGHTS AS OF JANUARY
1,
2021, WERE ADMITTED TO TRADING ON STOCK EXCHANGE ON APRIL 16,
2021
Source text for Eikon: ID:nEQ6dWTBa
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns